Wedbush maintains Janux Therapeutics at Outperform, raises price target to $40 from $36

Wedbush maintained Janux Therapeutics at Outperform and raised its price target to $40 from $36, an 11.1% increase.

The price target implies an upside of 149.1% from the Nov 5 close of $16.06.

Explore more price target data and ratings for Janux Therapeutics on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.